With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.173035-10-4,1,3-Dimesityl-4,5-dihydro-1H-imidazol-3-ium chloride,as a common compound, the synthetic route is as follows.
A suspension of 6.52 g (17.55 mmol) of l,3-bis(2,4,6-trimethylphenyl)-imidazolidinium chloride (commercially available from Umicore AG, D-63457 Hanau- Wolfgang) and 11.40 ml (19.38 mmol) of potassium tert-.pentylate (1.7 M in toluene) in 400 ml of hexane was stirred for 10 min at 500C. After the reaction mixture was evaporated to dryness, the white residue was re- dissolved in 400 ml of hexane and the formed suspension was transferred to a suspension of 4.00 g (5.85 mmol) of [RuCl2(=CH(o-OCH(Me)CO-N-Pyrrolidine)Ph)(PCy3)] in 400 ml of hexane. The resulting reaction mixture was stirred for 23 h at 500C. The formed green suspension was filtered, the filter cake was washed with 60 ml of hexane and dissolved in 50 ml of dichloromethane. 140 ml of water was added, the organic layer was separated, dried over Na2SO4 and evaporated to dryness. The crude product was washed twice with 70 ml of ethyl
173035-10-4 1,3-Dimesityl-4,5-dihydro-1H-imidazol-3-ium chloride 2734917, achiral-catalyst compound, is more and more widely used in various.
Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; WO2009/124853; (2009); A1;,
Chiral Catalysts
Chiral catalysts – SlideShare